One Wealth Management Investment & Advisory Services LLC Has $350,000 Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

One Wealth Management Investment & Advisory Services LLC boosted its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 747 shares of the pharmaceutical company’s stock after purchasing an additional 24 shares during the quarter. One Wealth Management Investment & Advisory Services LLC’s holdings in Vertex Pharmaceuticals were worth $350,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Groesbeck Investment Management Corp NJ lifted its holdings in shares of Vertex Pharmaceuticals by 1.2% in the 2nd quarter. Groesbeck Investment Management Corp NJ now owns 1,794 shares of the pharmaceutical company’s stock worth $841,000 after acquiring an additional 21 shares during the last quarter. Institute for Wealth Management LLC. lifted its holdings in shares of Vertex Pharmaceuticals by 0.6% in the 2nd quarter. Institute for Wealth Management LLC. now owns 3,586 shares of the pharmaceutical company’s stock worth $1,681,000 after acquiring an additional 22 shares during the last quarter. Drive Wealth Management LLC lifted its holdings in shares of Vertex Pharmaceuticals by 2.0% in the 2nd quarter. Drive Wealth Management LLC now owns 1,101 shares of the pharmaceutical company’s stock worth $516,000 after acquiring an additional 22 shares during the last quarter. RFP Financial Group LLC lifted its holdings in shares of Vertex Pharmaceuticals by 17.0% in the 2nd quarter. RFP Financial Group LLC now owns 158 shares of the pharmaceutical company’s stock worth $74,000 after acquiring an additional 23 shares during the last quarter. Finally, Hohimer Wealth Management LLC lifted its holdings in shares of Vertex Pharmaceuticals by 0.8% in the 4th quarter. Hohimer Wealth Management LLC now owns 2,932 shares of the pharmaceutical company’s stock worth $1,193,000 after acquiring an additional 24 shares during the last quarter. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ:VRTX traded down $0.57 during trading on Friday, hitting $468.00. The company’s stock had a trading volume of 1,090,355 shares, compared to its average volume of 1,205,450. The company has a 50-day moving average of $483.31 and a 200-day moving average of $448.38. Vertex Pharmaceuticals Incorporated has a 12 month low of $341.85 and a 12 month high of $510.64. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.52 and a quick ratio of 2.26. The firm has a market cap of $120.77 billion, a price-to-earnings ratio of 30.37 and a beta of 0.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) EPS for the quarter, missing analysts’ consensus estimates of ($12.54) by ($0.29). Vertex Pharmaceuticals had a negative return on equity of 2.45% and a negative net margin of 4.74%. The firm had revenue of $2.65 billion for the quarter, compared to the consensus estimate of $2.66 billion. During the same quarter in the previous year, the business posted $3.53 EPS. Vertex Pharmaceuticals’s revenue was up 6.1% on a year-over-year basis. On average, sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post -1.85 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on VRTX. Redburn Atlantic started coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, June 27th. They set a “buy” rating and a $545.00 price objective on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Friday, July 26th. Canaccord Genuity Group upped their target price on shares of Vertex Pharmaceuticals from $371.00 to $376.00 and gave the stock a “sell” rating in a research report on Wednesday, July 31st. Barclays downgraded shares of Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and upped their target price for the stock from $472.00 to $509.00 in a research report on Monday, August 5th. Finally, TD Cowen upped their target price on shares of Vertex Pharmaceuticals from $450.00 to $500.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $485.91.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Sangeeta N. Bhatia sold 646 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $500.00, for a total transaction of $323,000.00. Following the completion of the sale, the director now directly owns 4,435 shares of the company’s stock, valued at approximately $2,217,500. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, Director Sangeeta N. Bhatia sold 646 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $500.00, for a total value of $323,000.00. Following the completion of the sale, the director now directly owns 4,435 shares in the company, valued at $2,217,500. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Chairman Jeffrey M. Leiden sold 3,784 shares of Vertex Pharmaceuticals stock in a transaction on Friday, August 30th. The stock was sold at an average price of $499.00, for a total value of $1,888,216.00. Following the sale, the chairman now owns 9,994 shares of the company’s stock, valued at $4,987,006. The disclosure for this sale can be found here. Insiders sold a total of 43,615 shares of company stock valued at $21,417,310 in the last three months. 0.20% of the stock is currently owned by corporate insiders.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.